Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

Schepens, Mass. Eye and Ear to create world's largest ophthalmology research center

The Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute announced today that they are combining forces to create the world's largest and most robust basic and clinical ophthalmology research enterprise with full spectrum bench-to-bedside research that will translate more quickly into better treatment for blinding diseases and ultimately cures.

10 Jun 2011

Adaptive optics technology reveals eye's cellular structure with unprecedented detail

Scientists today reported that the tiny light-sensing cells known as rods have been clearly and directly imaged in the living eye for the first time. Using adaptive optics (AO), the same technology astronomers use to study distant stars and galaxies, scientists can see through the murky distortion of the outer eye, revealing the eye's cellular structure with unprecedented detail.

9 Jun 2011

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

The new Montefiore Laser and Eye Center recently opened its doors to provide comprehensive care to Westchester patients at the Montefiore Medical Specialists of Westchester in Scarsdale, New York. Seven board-certified ophthalmologists from the Department of Ophthalmology and Visual Sciences at Montefiore Medical Center provide patients with specialty emphasis in pediatric ophthalmology, oculoplastic surgery, glaucoma, cornea and laser refractive surgery.

8 Jun 2011

Natural killer cells promote induction of dry eye disease: New discovery

If you are one of the millions of people around the world who struggle with dry eye disease, good news is on the way. A new research discovery published in the Journal of Leukocyte Biology offers hope for new drugs that treat the cellular cause of the disease rather than its symptoms.

1 Jun 2011

Research: Gene mutation causes eye disease glaucoma

It is a mutation in a gene that causes the eye disease glaucoma, according to collaborative research conducted by Swedish, Tunisian, and American researchers. The findings were recently published in the journal Nature Genetics.

31 May 2011

Modified vitamin A drug may help prevent age-related macular degeneration

Slowing down the aggregation or "clumping" of vitamin A in the eye may help prevent vision loss caused by macular degeneration, research from Columbia University Medical Center has found.

19 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial

SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.

4 May 2011

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME Study of ILUVIEN for the treatment of Diabetic Macular Edema at the 2011 ARVO Annual Meeting.

4 May 2011

Scientists discover new gene underlying angle-closure glaucoma

Jackson Laboratory researchers and their collaborators have reported their discovery of a gene implicated in an acute and severe form of glaucoma known as angle-closure glaucoma.

3 May 2011

SERI selects AB SCIEX TripleTOF 5600 system to test chronic eye inflammations

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute, an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOF™ 5600 System.

20 Apr 2011

Older women with high vitamin D status less likely to have early AMD

Women under the age of 75 with high vitamin D status were less likely to have early age-related macular degeneration, the leading cause of irreversible vision loss in adults, a University at Buffalo study has shown. The disease affects approximately 9 percent of Americans aged 40 and older.

12 Apr 2011

Study: Patients with glaucoma experience psychological problems

Fear of the unknown is one of the greatest issues facing patients with glaucoma - the second leading cause of blindness worldwide after cataracts - according to research in the April issue of the Journal of Advanced Nursing. People also worry about how the eye disease, which can be hereditary, will affect other members of their family.

11 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Optometrists congratulate Ontario government for progressive health policy

Ontarians will enjoy better access to eye health care now that optometrists can prescribe medications for sight-threatening conditions like eye infections and glaucoma.

7 Apr 2011

Scientists identify biological pathways that mediate IgA nephropathy

For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

IOVS journal publishes first global consensus report on MGD

The first global consensus report on meibomian gland dysfunction - a major cause of lid disease and evaporative dry eye - has been published in a special issue of the Investigative Ophthalmology & Visual Science journal.

1 Apr 2011

Study: People who have survived diabetes for many decades exhibit few complications

Over time, diabetes can wreak havoc on the body's eyes, cardiovascular system, kidneys and nerves. A major study by Joslin Diabetes Center researchers, however, has found that some people who have survived diabetes for many decades exhibit remarkably few complications—a discovery that points toward the presence of protective factors that guard against the disease's effects.

31 Mar 2011

SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology Annual Meeting being held May 1–May 5, 2011, in Fort Lauderdale, Florida.

25 Mar 2011